SIRNAOMICS Email Format
Biotechnology ResearchMaryland, United States11-50 Employees
Sirnaomics is a biotechnology research company focused on discovery and development of RNA therapeutics for unmet medical needs and large market opportunities. The company relies on proprietary RNA interference delivery technologies, including a polypeptide nanoparticle RNAi platform and GalAhead RNAi platforms (GalAhead mxRNA and GalAhead muRNA), to advance its drug candidate pipeline. Headquartered in Germantown, Maryland, Sirnaomics maintains a presence in Asia and the United States. Its pipeline includes STP122G, a GalAhead mxRNA-based candidate in Phase I development, and STP125G, targeting ApoC3 mRNA for cardiovascular disease. STP237G is a dual-targeted candidate based on GalAhead muRNA in late-stage preclinical evaluation, and the company also pursues oncology programs such as STP705 and STP707. The group operates a manufacturing facility to support its expanding clinical pipeline and employs 11-50 people.